LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY

Abstract Activation of the MAPK pathway represents a hallmark of pediatric low-grade glioma (pLGG) and is frequently caused by BRAF alterations. BRAF-V600E represent an aggressive type of pLGG with less than optimal response to conventional chemo-radiation approaches. While clinical trials using BRA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2018-06, Vol.20 (suppl_2), p.i117-i117
Hauptverfasser: Zapotocky, Michal, Ryall, Scott, Fukuoka, Kohei, Stucklin, Ana Guerreiro, Bennett, Julie, Sumerauer, David, Pavelka, Zdenek, Cruz, Ofelia, Solano, Palma, Garre, Maria Luisa, Hauser, Peter, Frappaz, Didier, Hansford, Jordan, Amayiri, Nisreen, Morse, Helena, Sabel, Magnus, Bechensteen, Anne Grete, Su, Jack, Karajannis, Matthias, Finlay, Jonathan, Eisenstat, David, Canete, Adela, Toledano, Helen, Dahiya, Sonika, Leary, Sarah, Nicolaides, Theodore, Finch, Elisabeth, Mueller, Sabine, Levy, Jean Mulcahy, Ellison, David, Lassaletta, Alvaro, Larouche, Valerie, Ramaswamy, Vijay, Dirks, Peter, McKeown, Tara, Bartels, Ute, Bouffet, Eric, Hawkins, Cynthia, Tabori, Uri
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Activation of the MAPK pathway represents a hallmark of pediatric low-grade glioma (pLGG) and is frequently caused by BRAF alterations. BRAF-V600E represent an aggressive type of pLGG with less than optimal response to conventional chemo-radiation approaches. While clinical trials using BRAF-V600E inhibitors are ongoing, these data are not yet available. We have assembled an international cohort of BRAF-V600E glioma patients treated off-label with BRAF inhibitors as a monotherapy. Complete molecular, clinical and imaging data is being collected and compared to previous chemo-radiation therapies. Ongoing data form the taskforce on 40 BRAF-V600E gliomas from 25 international institutions is summarized below. The most prevalent histologies were ganglioglioma, pilocytic astrocytoma and pleomorphic xanthoastrocytoma, located mainly in the chiasm, brainstem and temporal lobes. Strikingly, 66% of BRAF V600E pLGG patients achieved partial response (PR) to targeted inhibitors versus only 6.6% response to conventional chemotherapy (p
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noy059.399